In a phase I clinical trial involving patients with advanced or metastatic pancreatic cancer, VCN-01 enhanced the infiltration of CD8+ T cells and the upregulation of indole 2,3-dioxygenase, resulting in clinical response rates of 40 to 45% (173). This evidence concerns the gene CD8A and pancreatic neoplasm.